Proteasome inhibitor-based therapy for antibody-mediated rejection

Kidney International

Volumn 81, Issue 11, 2012, Pages 1067-1074

  Walsh, R Carlin ^a   Alloway, Rita R ^a   Girnita, Alin L ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

antibody mediated rejection; bortezomib; proteasome inhibition

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPEPTIDE BORONIC ACID; METHYLPREDNISOLONE; PROTEASOME; PROTEASOME INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ANEMIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BONE MARROW BIOPSY; CARDIAC GRAFT REJECTION; CLINICAL PROTOCOL; CONJUNCTIVITIS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALOMYELITIS; ENZYME INHIBITION; FEBRILE NEUTROPENIA; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY ALLOGRAFT REJECTION; MULTIPLE CYCLE TREATMENT; MYELOMA; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PLASMAPHERESIS; POLYARTHRITIS; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VASCULITIS; VOMITING; WEAKNESS;

EID: 84861183296     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.502     Document Type: Review

References (42)

1. Lee PC, Zhu L, Terasaki PI et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568-574.
2. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415. (Pubitemid 46096334)
3. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871. (Pubitemid 46481194)
4. Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
5. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
6. Ramos EJ, Pollinger HS, Stegall MD et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-407. (Pubitemid 46096333)
7. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
8. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999; 274: 22123-22126.
9. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29: 3-9. (Pubitemid 36626287)
10. Goldberg AL, Cascio P, Saric T et al. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 2002; 39: 147-164. (Pubitemid 35013508)
11. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHCclass- I-mediated antigen presentation. Curr Opin Immunol 2004; 16: 76-81. (Pubitemid 38198120)
12. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitinproteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-685.
13. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003; 4: 1-10.
14. Yew PR. Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators. J Cell Physiol 2001; 187: 1-10.
15. Kim R, Emi M, Tanabe K et al. Role of the unfolded protein response in cell death. Apoptosis 2006; 11: 5-13. (Pubitemid 43151639)
16. Obeng EA, Carlson LM, Gutman DM et al. Proteasome inhbitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916. (Pubitemid 43882644)
17. Mattingly LH, Gault RA, Murphy WJ. Use of systemic proteasome inhibition as an immune-modulating agent in disease. Endocr Metab Immune Disord Drug Targets 2007; 7: 29-34. (Pubitemid 46380416)
18. Luo H, Wu Y, Qi S et al. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001; 72: 196-202. (Pubitemid 32729334)
19. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755. (Pubitemid 351951516)
20. Vanderlugt CL, Rahbe SM, Elliott PJ et al. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 2000; 14: 205-211.
21. Palombella VJ, Conner EM, Fuseler JW et al. Role of the proteasome and NK-kB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-15676. (Pubitemid 29018758)
22. Wu Y, Han B, Luo H et al. Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection. Transplantation 2004; 78: 360-366. (Pubitemid 39095401)
23. Ashton-Chess J, Mai HL, Jovanovic V et al. Immunoproteasome beta subunit 10 is increased in chronic antibody mediated rejection. Kidney Int 2010; 77: 880-890.
24. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364-370. (Pubitemid 40615791)
25. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
26. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681-686.
27. Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
28. Kraus ES, Parekh RS, Oberai P et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9: 1826-1834.
29. Hass M, Montgomery RA, Segev DL et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-585. (Pubitemid 46376440)
30. Walsh RC, Brailey P, Girnita A et al. Proteasome inhibitor-based antihumoral therapy: differential response in early vs. late antibody mediated rejection. Transplantation 2011; 91: 1218-1226.
31. Meister S, Schubert U, Neubert K et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-1792. (Pubitemid 46383406)
32. Flechner SM, Fatica R, Askar M et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492.
33. Woodle ES, Light J, Rubin M et al. Proteasome inhibitor therapy for antibody mediated rejection: initial report from a multicenter collaborative. Am J Transplant 2010; 10(s4): 83-84. [Abstract 146].
34. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
35. Zarkhin V, Li L, Kambham N et al. A randomized, prospective trial of acute rejection in pediatric renal transplantation. Am J Tranplant 2008; 8: 2607-2617.
36. Bross PF, Kane R, Farrell AT et al. Approval summary for bortezomib for injectiion in the treatment of myltiple myeloma. Clin Cancer Res 2004; 10: 3954-3964. (Pubitemid 38812468)
37. Raghavaiah SR, Diwan TS, Burns JM et al. Depletion of alloantibodysecreting plasma cells by proteasome inhibition improves desensitization. Am J Transplant 2010; 10(s4): 44-45 (abstract 22).
38. Dick LR, Flemin PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010; 15: 243-249.
39. Neumann J, Tarrasconi H, Bortolotto A et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation 2010; 89: 125-126.
40. Govil A, Walsh RC, Tevar A et al. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients. Clin Transpl 2010: 443-453.
41. Morrow WR, Frazier E, Mahle W et al. Proteasome inhibitor-based therapy for antibody mediated rejection in pediatric heart transplantation. Am J Transplant 2010; 10(Suppl 4): 93-94 (abstract 177).
42. Woodle ES, Gebel H. Regulatory approval for new antihumoral therapies: addressing the barriers. Am J Transplant 2011; 11: 880-881.